Cargando…

Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study

NVA237 (glycopyrronium bromide) is a once-daily long-acting muscarinic antagonist (LAMA) in development for chronic obstructive pulmonary disease (COPD). The GLycopyrronium bromide in COPD airWays clinical Study 2 (GLOW2) evaluated the efficacy and safety of NVA237 in moderate-to-severe COPD over 52...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kerwin, Edward, Hébert, Jacques, Gallagher, Nicola, Martin, Carmen, Overend, Tim, Alagappan, Vijay K.T., Lu, Yimeng, Banerji, Donald
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2012
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3485572/ https://www.ncbi.nlm.nih.gov/pubmed/23060624 http://dx.doi.org/10.1183/09031936.00040712

Ejemplares similares

Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial
por: D'Urzo, Anthony, et al.
Publicado: (2011)

Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial
por: Beeh, Kai M, et al.
Publicado: (2012)

Role of once-daily glycopyrronium bromide (NVA237) in the management of COPD
por: D’Urzo, Anthony
Publicado: (2013)

A novel model-based approach for dose determination of glycopyrronium bromide in COPD
por: Arievich, Helen, et al.
Publicado: (2012)

A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study
por: Chapman, Kenneth R, et al.
Publicado: (2014)

Effects of tiotropium + olodaterol versus tiotropium or placebo by COPD disease severity and previous treatment history in the OTEMTO® studies
por: Singh, Dave, et al.
Publicado: (2016)

Role of tiotropium in the treatment of COPD
por: Rice, Kathryn L, et al.
Publicado: (2007)

Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study
por: Dahl, Ronald, et al.
Publicado: (2013)

The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD
por: Anzueto, Antonio R, et al.
Publicado: (2017)

Tiotropium/Olodaterol: A Review in COPD
por: Blair, Hannah A.
Publicado: (2019)

Preventing and managing exacerbations in COPD – critical appraisal of the role of tiotropium
por: Tashkin, Donald P
Publicado: (2010)

Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium
por: Vogelmeier, Claus, et al.
Publicado: (2010)

Tiotropium in patients with moderate COPD naive to maintenance therapy: a randomised placebo-controlled trial
por: Troosters, Thierry, et al.
Publicado: (2014)

Tiotropium/olodaterol versus tiotropium in Japanese patients with COPD: results from the DYNAGITO study
por: Ichinose, Masakazu, et al.
Publicado: (2018)

Tiotropium HandiHaler(®) in the treatment of COPD: A safety review
por: Kesten, Steven, et al.
Publicado: (2009)

CoNVaQ: a web tool for copy number variation-based association studies
por: Larsen, Simon Jonas, et al.
Publicado: (2018)

Correction to: Tiotropium/Olodaterol: A Review in COPD
por: Blair, Hannah A.
Publicado: (2019)

Tiotropium/olodaterol versus tiotropium in Japanese patients with COPD: results from the DYNAGITO study [Corrigendum]
Publicado: (2018)

Cost-Effectiveness Analysis of Fixed-Dose Tiotropium/Olodaterol versus Tiotropium for COPD Patients in China
por: Lan, Ying, et al.
Publicado: (2023)

Pharmacologic rationale underlying the therapeutic effects of tiotropium/olodaterol in COPD
por: Pelaia, Girolamo, et al.
Publicado: (2015)

Tiotropium HandiHaler(®) and Respimat(®) in COPD: a pooled safety analysis
por: Halpin, David MG, et al.
Publicado: (2015)

Dual bronchodilation with tiotropium/olodaterol further reduces activity-related breathlessness versus tiotropium alone in COPD
por: Maltais, François, et al.
Publicado: (2019)

Effect of add-on therapy of tiotropium in COPD treated with theophylline
por: Kawayama, Tomotaka, et al.
Publicado: (2008)

Socioeconomic gradients in tiotropium use among adults with COPD
por: Blanc, Paul D, et al.
Publicado: (2008)

The effect of tiotropium therapy on markers of elastin degradation in COPD
por: Ma, Shuren, et al.
Publicado: (2009)

Safety, tolerability and risk benefit analysis of tiotropium in COPD
por: Oba, Yuji, et al.
Publicado: (2008)

Efficacy of tiotropium–olodaterol fixed-dose combination in COPD
por: Derom, Eric, et al.
Publicado: (2016)

Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4)
por: Buhl, Roland, et al.
Publicado: (2015)

A Dose-Ranging Study of the Novel Inhaled Dual PDE 3 and 4 Inhibitor Ensifentrine in Patients with COPD Receiving Maintenance Tiotropium Therapy
por: Ferguson, Gary T, et al.
Publicado: (2021)

Use of tiotropium in patients with COPD aged 80 years and older
por: SATOH, HIROAKI, et al.
Publicado: (2013)

Quality of life and adherence to inhaled corticosteroids and tiotropium in COPD are related
por: Koehorst-ter Huurne, Kirsten, et al.
Publicado: (2016)

Umeclidinium/vilanterol as step-up therapy from tiotropium in patients with moderate COPD: a randomized, parallel-group, 12-week study
por: Kerwin, Edward M, et al.
Publicado: (2017)

SPOTlight on GLOW
por: Derks, Sarah, et al.
Publicado: (2023)

A randomized, crossover, placebo controlled, double-blind trial of the effects of tiotropium-olodaterol on neuromuscular performance during exercise in COPD
por: Cao, Min, et al.
Publicado: (2022)

Benefits of Tiotropium/Olodaterol Compared with Tiotropium in Patients with COPD Receiving only LAMA at Baseline: Pooled Analysis of the TONADO(®) and OTEMTO(®) Studies
por: Buhl, Roland, et al.
Publicado: (2020)

TRONARTO: A Randomized, Placebo-Controlled Study of Tiotropium/Olodaterol Delivered via Soft Mist Inhaler in COPD Patients Stratified by Peak Inspiratory Flow
por: Mahler, Donald A, et al.
Publicado: (2021)

Small airways ventilation heterogeneity and hyperinflation in COPD: Response to tiotropium bromide
por: Verbanck, Sylvia, et al.
Publicado: (2007)

Tiotropium and exercise training in COPD patients: Effects on dyspnea and exercise tolerance
por: Ambrosino, Nicolino, et al.
Publicado: (2008)

Tiotropium might improve survival in subjects with COPD at high risk of mortality
por: Burgel, Pierre-Régis, et al.
Publicado: (2014)

Effects of combined tiotropium/olodaterol on inspiratory capacity and exercise endurance in COPD
por: O'Donnell, Denis E., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_if12f8gft6ub2hlmak8na45evu